25 results on '"Slisz J"'
Search Results
2. Transplantation tolerance prevents cardiac allograft vasculopathy in major histocompatibility complex class I-disparate miniature swine.
- Author
-
Madsen, J. C., Yamada, K., Allan, J. S., Choo, J. K., Erhorn, IV, A. E., Pins, I. R., Vesga, L., Slisz, J. K., and Sachs, D. H.
- Published
- 1998
- Full Text
- View/download PDF
Catalog
3. Monitoring of fluid replacement in extensively burned patients with oliguric renal insufficiency
- Author
-
Dobke M, Wyrzykowski B, Kondrat W, Jaromczyk-Slisz J, and Anna Dominiczak
- Subjects
Adult ,Male ,Adolescent ,Fluid Therapy ,Humans ,Female ,Acute Kidney Injury ,Burns ,Monitoring, Physiologic - Published
- 1981
4. Widespread haploid-biased gene expression enables sperm-level natural selection.
- Author
-
Bhutani K, Stansifer K, Ticau S, Bojic L, Villani AC, Slisz J, Cremers CM, Roy C, Donovan J, Fiske B, and Friedman RC
- Subjects
- Animals, Conserved Sequence, Genetic Markers, Humans, Male, Mice, Mice, Inbred C57BL, Sex Chromosomes genetics, Single-Cell Analysis, Spermatids metabolism, Testis metabolism, Gene Expression, Haploidy, Selection, Genetic, Spermatozoa metabolism
- Abstract
Sperm are haploid but must be functionally equivalent to distribute alleles equally among progeny. Accordingly, gene products are shared through spermatid cytoplasmic bridges that erase phenotypic differences between individual haploid sperm. Here, we show that a large class of mammalian genes are not completely shared across these bridges. We call these genes "genoinformative markers" (GIMs) and show that a subset can act as selfish genetic elements that spread alleles unevenly through murine, bovine, and human populations. We identify evolutionary pressure to avoid conflict between sperm and somatic function as GIMs are enriched for testis-specific gene expression, paralogs, and isoforms. Therefore, GIMs and sperm-level natural selection may help to explain why testis gene expression patterns are an outlier relative to all other tissues., (Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.) more...
- Published
- 2021
- Full Text
- View/download PDF
5. Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer.
- Author
-
LaMarche MJ, Acker M, Argintaru A, Bauer D, Boisclair J, Chan H, Chen CH, Chen YN, Chen Z, Deng Z, Dore M, Dunstan D, Fan J, Fekkes P, Firestone B, Fodor M, Garcia-Fortanet J, Fortin PD, Fridrich C, Giraldes J, Glick M, Grunenfelder D, Hao HX, Hentemann M, Ho S, Jouk A, Kang ZB, Karki R, Kato M, Keen N, Koenig R, LaBonte LR, Larrow J, Liu G, Liu S, Majumdar D, Mathieu S, Meyer MJ, Mohseni M, Ntaganda R, Palermo M, Perez L, Pu M, Ramsey T, Reilly J, Sarver P, Sellers WR, Sendzik M, Shultz MD, Slisz J, Slocum K, Smith T, Spence S, Stams T, Straub C, Tamez V Jr, Toure BB, Towler C, Wang P, Wang H, Williams SL, Yang F, Yu B, Zhang JH, and Zhu S more...
- Subjects
- Allosteric Regulation drug effects, Allosteric Regulation physiology, Animals, Antineoplastic Agents therapeutic use, Dogs, Enzyme Inhibitors chemistry, Enzyme Inhibitors pharmacology, Enzyme Inhibitors therapeutic use, Humans, Macaca fascicularis, Mice, Neoplasms drug therapy, Neoplasms pathology, Rats, Tumor Cells, Cultured, Xenograft Model Antitumor Assays methods, Antineoplastic Agents chemistry, Antineoplastic Agents pharmacology, Neoplasms enzymology, Protein Tyrosine Phosphatase, Non-Receptor Type 11 antagonists & inhibitors, Protein Tyrosine Phosphatase, Non-Receptor Type 11 metabolism
- Abstract
SHP2 is a nonreceptor protein tyrosine phosphatase encoded by the PTPN11 gene and is involved in cell growth and differentiation via the MAPK signaling pathway. SHP2 also plays an important role in the programed cell death pathway (PD-1/PD-L1). As an oncoprotein as well as a potential immunomodulator, controlling SHP2 activity is of high therapeutic interest. As part of our comprehensive program targeting SHP2, we identified multiple allosteric binding modes of inhibition and optimized numerous chemical scaffolds in parallel. In this drug annotation report, we detail the identification and optimization of the pyrazine class of allosteric SHP2 inhibitors. Structure and property based drug design enabled the identification of protein-ligand interactions, potent cellular inhibition, control of physicochemical, pharmaceutical and selectivity properties, and potent in vivo antitumor activity. These studies culminated in the discovery of TNO155, (3 S ,4 S )-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine ( 1 ), a highly potent, selective, orally efficacious, and first-in-class SHP2 inhibitor currently in clinical trials for cancer. more...
- Published
- 2020
- Full Text
- View/download PDF
6. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
- Author
-
Chen YN, LaMarche MJ, Chan HM, Fekkes P, Garcia-Fortanet J, Acker MG, Antonakos B, Chen CH, Chen Z, Cooke VG, Dobson JR, Deng Z, Fei F, Firestone B, Fodor M, Fridrich C, Gao H, Grunenfelder D, Hao HX, Jacob J, Ho S, Hsiao K, Kang ZB, Karki R, Kato M, Larrow J, La Bonte LR, Lenoir F, Liu G, Liu S, Majumdar D, Meyer MJ, Palermo M, Perez L, Pu M, Price E, Quinn C, Shakya S, Shultz MD, Slisz J, Venkatesan K, Wang P, Warmuth M, Williams S, Yang G, Yuan J, Zhang JH, Zhu P, Ramsey T, Keen NJ, Sellers WR, Stams T, and Fortin PD more...
- Subjects
- Allosteric Regulation drug effects, Animals, Cell Line, Tumor, Cell Proliferation drug effects, Extracellular Signal-Regulated MAP Kinases metabolism, Female, Humans, Inhibitory Concentration 50, MAP Kinase Signaling System drug effects, Mice, Mice, Nude, Models, Molecular, Neoplasms pathology, Oncogene Protein p21(ras) metabolism, Piperidines chemistry, Piperidines therapeutic use, Protein Kinase Inhibitors pharmacology, Protein Stability drug effects, Protein Structure, Tertiary drug effects, Protein Tyrosine Phosphatase, Non-Receptor Type 11 chemistry, Protein Tyrosine Phosphatase, Non-Receptor Type 11 genetics, Protein Tyrosine Phosphatase, Non-Receptor Type 11 metabolism, Pyrimidines chemistry, Pyrimidines therapeutic use, Reproducibility of Results, Xenograft Model Antitumor Assays, Neoplasms drug therapy, Neoplasms enzymology, Piperidines pharmacology, Protein Tyrosine Phosphatase, Non-Receptor Type 11 antagonists & inhibitors, Pyrimidines pharmacology, Receptor Protein-Tyrosine Kinases metabolism
- Abstract
The non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, has an important role in signal transduction downstream of growth factor receptor signalling and was the first reported oncogenic tyrosine phosphatase. Activating mutations of SHP2 have been associated with developmental pathologies such as Noonan syndrome and are found in multiple cancer types, including leukaemia, lung and breast cancer and neuroblastoma. SHP2 is ubiquitously expressed and regulates cell survival and proliferation primarily through activation of the RAS–ERK signalling pathway. It is also a key mediator of the programmed cell death 1 (PD-1) and B- and T-lymphocyte attenuator (BTLA) immune checkpoint pathways. Reduction of SHP2 activity suppresses tumour cell growth and is a potential target of cancer therapy. Here we report the discovery of a highly potent (IC50 = 0.071 μM), selective and orally bioavailable small-molecule SHP2 inhibitor, SHP099, that stabilizes SHP2 in an auto-inhibited conformation. SHP099 concurrently binds to the interface of the N-terminal SH2, C-terminal SH2, and protein tyrosine phosphatase domains, thus inhibiting SHP2 activity through an allosteric mechanism. SHP099 suppresses RAS–ERK signalling to inhibit the proliferation of receptor-tyrosine-kinase-driven human cancer cells in vitro and is efficacious in mouse tumour xenograft models. Together, these data demonstrate that pharmacological inhibition of SHP2 is a valid therapeutic approach for the treatment of cancers. more...
- Published
- 2016
- Full Text
- View/download PDF
7. IAP inhibitors enhance co-stimulation to promote tumor immunity.
- Author
-
Dougan M, Dougan S, Slisz J, Firestone B, Vanneman M, Draganov D, Goyal G, Li W, Neuberg D, Blumberg R, Hacohen N, Porter D, Zawel L, and Dranoff G
- Subjects
- Animals, Antigens, Neoplasm immunology, Cancer Vaccines, Humans, Immunomodulation, Inhibitor of Apoptosis Proteins immunology, Inhibitor of Apoptosis Proteins metabolism, Mice, NF-kappa B immunology, NF-kappa B metabolism, Neoplasms metabolism, Tumor Necrosis Factor-alpha immunology, Tumor Necrosis Factor-alpha metabolism, Inhibitor of Apoptosis Proteins antagonists & inhibitors, Neoplasms immunology, Signal Transduction, T-Lymphocytes immunology
- Abstract
The inhibitor of apoptosis proteins (IAPs) have recently been shown to modulate nuclear factor κB (NF-κB) signaling downstream of tumor necrosis factor (TNF) family receptors, positioning them as essential survival factors in several cancer cell lines, as indicated by the cytotoxic activity of several novel small molecule IAP antagonists. In addition to roles in cancer, increasing evidence suggests that IAPs have an important function in immunity; however, the impact of IAP antagonists on antitumor immune responses is unknown. In this study, we examine the consequences of IAP antagonism on T cell function in vitro and in the context of a tumor vaccine in vivo. We find that IAP antagonists can augment human and mouse T cell responses to physiologically relevant stimuli. The activity of IAP antagonists depends on the activation of NF-κB2 signaling, a mechanism paralleling that responsible for the cytotoxic activity in cancer cells. We further show that IAP antagonists can augment both prophylactic and therapeutic antitumor vaccines in vivo. These findings indicate an important role for the IAPs in regulating T cell-dependent responses and suggest that targeting IAPs using small molecule antagonists may be a strategy for developing novel immunomodulating therapies against cancer. more...
- Published
- 2010
- Full Text
- View/download PDF
8. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling.
- Author
-
Gaither A, Porter D, Yao Y, Borawski J, Yang G, Donovan J, Sage D, Slisz J, Tran M, Straub C, Ramsey T, Iourgenko V, Huang A, Chen Y, Schlegel R, Labow M, Fawell S, Sellers WR, and Zawel L
- Subjects
- Apoptosis drug effects, Apoptosis physiology, Apoptosis Regulatory Proteins, Cell Death, Cell Line, Tumor, Conserved Sequence, Female, Humans, Oligopeptides pharmacology, Ovarian Neoplasms, RNA Interference physiology, RNA, Neoplasm genetics, Signal Transduction, X-Linked Inhibitor of Apoptosis Protein genetics, Inhibitor of Apoptosis Proteins physiology, Intracellular Signaling Peptides and Proteins physiology, Mitochondrial Proteins physiology, RNA, Small Interfering genetics, Tumor Necrosis Factor-alpha physiology, X-Linked Inhibitor of Apoptosis Protein physiology
- Abstract
Smac mimetic compounds targeting the inhibitor of apoptosis proteins (IAP) baculoviral IAP repeat-3 domain are presumed to reduce the threshold for apoptotic cell death by alleviating caspase-9 repression. We explored this tenet in an unbiased manner by searching for small interfering RNAs that are able to confer resistance to the Smac mimetic compound LBW242. Among the screening hits were multiple components of the tumor necrosis factor alpha (TNFalpha) signaling pathway as well as X-linked inhibitor of apoptosis (XIAP) itself. Here, we show that in a subset of highly sensitive tumor cell lines, activity of LBW242 is dependent on TNFalpha signaling. Mechanistic studies indicate that in this context, XIAP is a positive modulator of TNFalpha induction whereas cellular inhibitor of apoptosis protein 1 negatively regulates TNFalpha-mediated apoptosis. more...
- Published
- 2007
- Full Text
- View/download PDF
9. Morphometric analysis of miniature swine hearts as potential human xenografts.
- Author
-
Allan JS, Rose GA, Choo JK, Arn JS, Vesga L, Mawulawde K, Slisz JK, Allison K, and Madsen JC
- Subjects
- Animals, Body Constitution, Echocardiography, Heart anatomy & histology, Heart Transplantation pathology, Humans, Swine, Swine, Miniature, Transplantation, Heterologous, Heart Transplantation methods
- Abstract
Miniature swine are considered to be potential donors for clinical cardiac transplantation. However, it is unclear how an appropriately sized porcine donor will be selected for a particular human recipient. To address this issue, we performed a morphometric study of the swine heart using transthoracic echocardiography (n = 26) to determine the diameters of the aortic annulus and root, pulmonary artery annulus, and mitral valve annulus. We also obtained direct ex vivo measurements of swine heart weight and linear dimensions (n = 71). Relationships between a swine's height, weight, length, chest circumference and these internal and external cardiac dimensions are described. The strongest correlations were found between a pig's body length and its aortic annulus and root diameters (r-values = 0.97). These relationships are accurately described by univariate linear regression models. By cross-relating our morphometric measurements of aortic annulus diameter in the miniature swine with normative human data, we were able to develop a nomogram, relating swine length and human height, which predicts which miniature swine would donate the best size-matched heart for a particular human recipient. more...
- Published
- 2001
- Full Text
- View/download PDF
10. Mechanisms of tolerance induction and prevention of cardiac allograft vasculopathy in miniature swine: the effect of augmentation of donor antigen load.
- Author
-
Yamada K, Mawulawde K, Menard MT, Shimizu A, Aretz HT, Choo JK, Allison KS, Slisz JK, Sachs DH, and Madsen JC
- Subjects
- Animals, Coronary Disease etiology, Coronary Disease immunology, Cyclosporine administration & dosage, Cytotoxicity, Immunologic, Graft Rejection immunology, Graft Rejection prevention & control, Heart Transplantation adverse effects, Immune Tolerance, Immunosuppressive Agents administration & dosage, Kidney Transplantation immunology, Leukocyte Transfusion, Major Histocompatibility Complex immunology, Myocardium pathology, Swine, Swine, Miniature, Thymectomy, Transplantation Chimera, Coronary Disease prevention & control, Graft Enhancement, Immunologic, Heart Transplantation immunology
- Abstract
Objective: Cotransplantation of a donor kidney along with a heart allograft can induce tolerance to both organs and prevent cardiac allograft vasculopathy in miniature swine. To determine whether the tolerogenic effect of donor kidney cotransplantation was due to an effect specific to the kidney graft or to an increase in donor antigen load, we compared heart-kidney recipients with recipients receiving two class I disparate hearts or with recipients receiving donor peripheral mononuclear cells at the time of isolated heart transplantation., Methods: Recipients of major histocompatibility complex class I disparate allografts received 12 days of cyclosporine (INN: cyclosporin; 10-13 mg/kg administered intravenously on days 0-11). Group 1 animals received a heart alone (n = 5). Group 2 animals received heart and kidney allografts (n = 4). Group 3 animals received two major histocompatibility complex-matched heart allografts (n = 4). Two double-heart recipients were thymectomized 21 days before transplantation. Group 4 animals received a heart allograft and an infusion of high-dose donor peripheral blood leukocytes (2.5 x 10(9) cells/kg, n = 2)., Results: Vasculopathy developed in group 1 recipients and the allografts were rejected within 55 days. Group 2 recipients accepted their heart and kidney allografts indefinitely without vasculopathy. Euthymic recipients from group 3 accepted their hearts long-term (>190 and >197 days), but vascular lesions developed. In thymectomized recipients from group 3, the hearts were rejected in 63 and 96 days with severe vasculopathy. Group 4 recipients demonstrated transient macrochimerism but their hearts were rejected within 47 and 63 days., Conclusions: The beneficial effects of donor kidney cotransplantation on cardiac allograft survival and prevention of cardiac allograft vasculopathy are likely to involve both an increase in donor antigen load and an effect specific to the kidney allograft. more...
- Published
- 2000
- Full Text
- View/download PDF
11. The effect of thymectomy on tolerance induction and cardiac allograft vasculopathy in a miniature swine heart/kidney transplantation model.
- Author
-
Yamada K, Choo JK, Allan JS, Erhorn AE, Menard MT, Mawulawde K, Slisz JK, Aretz HT, Shimizu A, Sachs DH, and Madsen JC
- Subjects
- Animals, Cyclosporine administration & dosage, Heart Transplantation adverse effects, Heart Transplantation pathology, Histocompatibility Antigens Class I, Immunosuppressive Agents administration & dosage, Models, Biological, Swine, Swine, Miniature, Thymectomy, Transplantation, Homologous, Vascular Diseases etiology, Vascular Diseases immunology, Vascular Diseases prevention & control, Heart Transplantation immunology, Immune Tolerance, Kidney Transplantation immunology, Thymus Gland immunology
- Abstract
Background: We have previously demonstrated that MHC class I disparate hearts transplanted into miniature swine treated with a short course of cyclosporine developed florid cardiac allograft vasculopathy (CAV) and were rejected within 55 days. However, when a donor-specific kidney is cotransplanted with the heart allograft, recipients become tolerant to donor antigen and accept both allografts long-term without the development of CAV. In the present study, we have investigated the role of the host thymus in the induction of tolerance and prevention of CAV in heart/kidney recipients., Methods: Total thymectomies were performed in six animals (postoperative day [POD]-21), which on day 0 received either an isolated MHC class I disparate heart allograft (n=3) or combined class I disparate heart and kidney allografts (n=3), followed in both cases by a 12-day course of cyclosporine (POD 0-11). Graft survival and the development of CAV in these thymectomized recipients were compared to the same parameters in non-thymectomized, cyclosporine-treated recipients bearing either class I disparate heart allografts (n=5) or heart and kidney allografts (n=4)., Results: In the group of animals bearing isolated class I disparate heart allografts, the thymectomized recipients rejected their allografts earlier (POD 8, 22, 27) than the non-thymectomized recipients (POD 33,35,45,47,55). The donor hearts in both the thymectomized and non-thymectomized animals developed florid CAV. In the group of animals bearing combined class I disparate heart and kidney allografts, the nonthymectomized recipients accepted both donor organs long term with no evidence of CAV. In contrast, none of the thymectomized heart/kidney recipients survived >100 days, and they all developed the intimal proliferation of CAV., Conclusion: Thymic-dependent mechanisms are necessary for the induction of acquired tolerance and prevention of CAV in porcine heart/kidney recipients. more...
- Published
- 1999
- Full Text
- View/download PDF
12. Morphometric analyses to predict appropriate donor size for swine-to-human cardiac xenotransplantation.
- Author
-
Allan JS, Rose GA, Choo JK, Arn JS, Vesga L, Mawulawde K, Slisz JK, Allison K, and Madsen JC
- Subjects
- Animals, Aorta anatomy & histology, Breeding, Echocardiography, Heart Valves anatomy & histology, Hemodynamics, Humans, Organ Size, Pulmonary Artery anatomy & histology, Regression Analysis, Swine, Heart anatomy & histology, Heart physiology, Heart Transplantation, Swine, Miniature anatomy & histology, Transplantation, Heterologous
- Published
- 1999
- Full Text
- View/download PDF
13. The effects of heart/kidney versus double heart transplantation on tolerance induction and prevention of cardiac allograft vasculopathy.
- Author
-
Yamada K, Menard MT, Mawulawde K, Slisz JK, Choo JK, Erhorn AE, Sachs DH, and Madsen JC
- Subjects
- Animals, Coronary Disease etiology, Graft Survival, Histocompatibility Testing, Immunosuppressive Agents therapeutic use, Kidney Transplantation pathology, Postoperative Complications prevention & control, Swine, Swine, Miniature, Thymectomy, Transplantation, Homologous, Coronary Disease prevention & control, Cyclosporine therapeutic use, Heart Transplantation immunology, Heart Transplantation pathology, Kidney Transplantation immunology
- Published
- 1999
- Full Text
- View/download PDF
14. Enhanced efficacy of repeated anti-CD8 monoclonal antibody therapy by high-dose cyclosporine treatment.
- Author
-
Allan JS, Slisz JK, Vesga L, Arn JS, Yamada K, Sachs DH, and Madsen JC
- Subjects
- Animals, Antibodies, Heterophile blood, Combined Modality Therapy, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Heart Transplantation immunology, Immunoglobulin G blood, Lymphocyte Depletion methods, Major Histocompatibility Complex, Mice, Swine, Swine, Miniature, Antibodies, Monoclonal therapeutic use, CD8-Positive T-Lymphocytes immunology, Cyclosporine therapeutic use, Immunosuppression Therapy methods, Immunosuppressive Agents therapeutic use
- Published
- 1998
- Full Text
- View/download PDF
15. Creation of the "thymoheart" allograft: implantation of autologous thymus into the heart prior to procurement.
- Author
-
Lambrigts D, Menard MT, Alexandre GP, Franssen C, Meurisse M, Van Calster P, Coignoul F, Mawulawde K, Choo JK, Yamada K, Erhorn AE, Slisz JK, Chiotellis P, Aretz HT, Sachs DH, and Madsen JC
- Subjects
- Animals, Heart Transplantation immunology, Histocompatibility Antigens Class I immunology, Histocompatibility Antigens Class I metabolism, Histocompatibility Antigens Class II immunology, Histocompatibility Antigens Class II metabolism, Swine, Swine, Miniature, Thymus Gland cytology, Thymus Gland immunology, Transplantation, Homologous methods, Heart Transplantation methods, Thymus Gland transplantation
- Abstract
Background: A state of tolerance may be more easily achieved if fully vascularized and functional donor thymus is transferred to the recipient at the time of whole organ transplantation., Methods: A composite "thymoheart" allograft was created by implanting autologous thymus into a donor heart 60-90 days before organ procurement. Successful intracardiac engraftment of autologous thymus was documented by histology and by flow cytometric analysis., Results: Histology of the thymic autografts at explantation revealed viable thymus with preservation of normal thymic architecture. Cells retrieved from thymic autografts 60 days after implantation exhibited the same MHC class I and class II staining profiles by flow cytometry as cells taken from the residual native thymus., Conclusion: We have created a novel composite organ that confers vascularized and functional donor thymus to heart allograft recipients at the time of transplantation without affecting cardiac function. more...
- Published
- 1998
- Full Text
- View/download PDF
16. [Indices of left heart ventricle relaxation after 5-months of hypotensive therapy with guanfacine].
- Author
-
Kubasik A, Rynkiewicz A, Jaromczyk-Slisz J, Jasiel-Wojculewicz H, and Krupa-Wojciechowska B
- Subjects
- Diabetic Angiopathies diagnostic imaging, Diastole physiology, Echocardiography, Female, Humans, Hypertension diagnostic imaging, Hypotension physiopathology, Male, Middle Aged, Diabetes Mellitus, Type 2 drug therapy, Diabetic Angiopathies drug therapy, Guanfacine therapeutic use, Hypertension drug therapy, Hypotension drug therapy, Ventricular Function, Left drug effects
- Abstract
The subject of the work is to assess the clinical parameters and diastolic function in patients with mild or moderate essential hypertension after 5-month treatment with guanfacine 0.5-3 mg/day, mean 1.7 mg. In the group there were 8 women and 8 men, mean age 53.7 +/- 7.6. The diastolic function of the left ventricle was assessed from the echocardiographic M-mode paper sweep of the left ventricle by the method of Gibson and Brown. In clinical parameters systolic, diastolic and mean blood pressure was found to decrease significantly, the heart rate was unchanged. Essential improvement of the markers of relaxation was received while amelioration of filling was not significant. The before treatment data were compared with the similar ones of the 60 persons of the control group. The significant differences were found in values of blood pressure, markers of relaxation and indices Iv and Ip. more...
- Published
- 1993
17. [Effect of 5-month guanfacine treatment on the renin-angiotensin-aldosterone system and some metabolic factors in patients with diabetes mellitus type II and hypertension].
- Author
-
Jaromczyk-Slisz J, Kubasik A, Jasiel-Wojculewicz H, Badzio T, and Krupa-Wojciechowska B
- Subjects
- Adult, Diabetes Mellitus, Type 2 blood, Female, Humans, Hypertension blood, Hypertension etiology, Male, Middle Aged, Diabetes Mellitus, Type 2 complications, Guanfacine therapeutic use, Hypertension drug therapy, Renin-Angiotensin System drug effects
- Abstract
The group of the investigated included 25 individuals (11 F, 14 M), aged 55 +/- 1.5 years, with diabetes type II and hypertension. Known diabetes duration was 4.9 +/- 0.8 years and known hypertension duration--7.4 +/- 1.4 years. Two weeks after administering placebo in place of hypertension drugs applied so far, guanfacine was included as the only hypertensive drug. The dosage was increased from 0.5 mg up to 3 mg daily until a good control of blood pressure was achieved. The diabetic treatment, diet and the smoking habit were unchanged. The resting activity of the renin-angiotension-aldosterone system (RAA), cholesterol, triglycerides, HDL and LDL, serum glucose levels and HbA1c were assayed after a 5-month guanfacine period. After treatment a significant decrease in blood pressure both systolic and diastolic (p < 0.001), heart rate (p < 0.005) and plasma renin activity (p < 0.02) were observed. Preliminary measurements of RAA activity and its changes during treatment were not helpful in predicting guanfacine hypotensive effect. The level of lipids, lipoproteins, atherogenic factors, glucose and HbA1c did not change significantly during the study. more...
- Published
- 1992
18. [Hyperglycemic hyperosmolar nonketotic coma].
- Author
-
Jaromczyk-Slisz J, Semetkowska-Jurkiewicz E, and Horoszek-Maziarz S
- Subjects
- Adolescent, Aged, Blood Glucose analysis, Combined Modality Therapy, Critical Care, Diabetes Mellitus, Type 1 blood, Diabetes Mellitus, Type 2 blood, Female, Humans, Hyperglycemic Hyperosmolar Nonketotic Coma blood, Hyperglycemic Hyperosmolar Nonketotic Coma therapy, Male, Middle Aged, Osmolar Concentration, Diabetes Mellitus, Type 1 complications, Diabetes Mellitus, Type 2 complications, Diabetic Coma diagnosis, Hyperglycemic Hyperosmolar Nonketotic Coma diagnosis
- Abstract
Ten patients with the syndrome of non-ketotic hyperosmolar coma are described. The mean age of the patients was 62.3 +/- 17.12 years. One patient was 16 years old. In 9 cases the patients had type II diabetes, one had type I diabetes. In 7 cases the coma was the first sign of diabetes. The factor predisposing in most cases was infection. In the treatment-acting insulin and hypotonic solutions were given. In 2 cases clinical signs of the DIS syndrome were observed manifesting themselves with local changes, including mental disturbances. Heparin was given with good effect. Three patients (30%) died in hospital. The cause of death was serious disease associated with this coma: pancreatitis and myocarditis, purulent bronchopneumonia, myocardial infarction. more...
- Published
- 1990
19. [Congenital hypothyroidism with thyroglobulin deficiency and substitutional albumin iodination].
- Author
-
Snarski A, Slisz J, and Gockowski K
- Subjects
- Adult, Congenital Hypothyroidism, Humans, Male, Hypothyroidism metabolism, Iodine blood, Serum Albumin metabolism, Thyroglobulin deficiency
- Published
- 1978
20. [Hemodynamic studies with the use of radio-iodinated serum albumin in burns].
- Author
-
Dobke M, Wyrzykowski B, Kondrat W, and Jaromczyk-Slisz J
- Subjects
- Adolescent, Adult, Female, Humans, Male, Serum Albumin, Radio-Iodinated, Burns physiopathology, Hemodynamics
- Published
- 1979
21. [Hypervolemia in burns].
- Author
-
Dobke M, Wyrzykowski B, Renkielska A, Jaromczyk-Slisz J, Snarski A, Gorczyński A, and Honory-Batko M
- Subjects
- Adult, Burns therapy, Female, Humans, Male, Middle Aged, Shock, Traumatic physiopathology, Water Intoxication etiology, Blood Volume, Burns physiopathology, Fluid Therapy adverse effects
- Published
- 1980
22. [Clinical evaluation of a new sulfonylurea derivative, preparation SPC-703, based on a 5-year observation].
- Author
-
Horoszek-Maziarz S, Berliński E, Jaromczyk-Slisz J, Rachoń K, Wójcikowski C, Słomiński M, Orłowska-Kunikowska E, and Krupa-Wojciechowska B
- Subjects
- Chlorpropamide therapeutic use, Clinical Trials as Topic, Humans, Time Factors, Tolbutamide therapeutic use, Diabetes Mellitus, Type 2 drug therapy, Hypoglycemic Agents therapeutic use, Sulfonylurea Compounds therapeutic use
- Published
- 1985
23. [Analysis of the cause of death in diabetic ketoacidosis based on 5 years of personal observation].
- Author
-
Semetkowska-Jurkiewicz E, Jaromczyk-Slisz J, and Horoszek-Maziarz S
- Subjects
- Adult, Aged, Diabetic Ketoacidosis therapy, Female, Humans, Male, Middle Aged, Survival Rate, Cause of Death, Diabetic Ketoacidosis mortality
- Abstract
The authors observed 53 cases of diabetic ketoacidosis treated with low doses of insulin. Mean age of the patients was 41 +/- 17 years, duration of diabetes mellitus 7.5 +/- 6.4 years. Ketoacidosis was due to: infections in 36%, other diseases in 7%, and cessation of insulin therapy in 25% of cases. Ketoacidosis was a first sign of diabetes mellitus in 19% of cases while causative factor was not detected in 13% of cases. At the admission to hospital mean blood pH was 7.02 +/- 0.15, mean bicarbonate concentration 6.17 +/- 3.45 mM/l, and glycaemia 40.6 +/- 16.8 mM/l. Therapy of ketoacidosis was complicated by hypopotassemia in 1 patient and transient hypoglycaemia in another patient. Five patients (9.6%) died. Infections, myocardial infarction, acute pancreatitis, pulmonary edema, and disseminated intravascular coagulation were the causes of deaths. more...
- Published
- 1989
24. [Case of acute protracted pancreatitis with massive ascites].
- Author
-
Jaromczyk-Slisz J and Sledziński Z
- Subjects
- Acute Disease, Adult, Humans, Male, Time Factors, Ascites complications, Pancreatitis complications
- Published
- 1978
25. [1-year observation of patients with adult-type diabetes treated with a new sulfonylurea derivative, SPC-703].
- Author
-
Horoszek-Maziarz S, Berliński E, Rachoń K, Jaromczyk-Slisz J, Wilk L, Wójcikowski C, and Krupa-Wojciechowska B
- Subjects
- Drug Evaluation, Female, Humans, Male, Pyrazoles therapeutic use, Time Factors, Diabetes Mellitus drug therapy, Sulfonylurea Compounds therapeutic use
- Published
- 1977
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.